Drug Database
SA

salbutamol (Inspiryl Turbuhaler)

✓ Approved

AstraZeneca UK Limited · ADRB2 · Small Molecule

What is salbutamol?

salbutamol is a small molecule developed by AstraZeneca UK Limited. It is approved for therapeutic indications via inhaled or topical.

Drug Profile

Brand NamesInspiryl Turbuhaler
CompanyAstraZeneca UK Limited
Drug ClassSmall Molecule
Molecular TargetADRB2
RouteInhaled, Topical
StatusApproved

Mechanism of Action

Molecular Targets

salbutamol acts on 1 molecular target:

ADRB2adrenoceptor beta 2 (B2AR, ARB2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

salbutamol is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved

Related Research Articles

PubMedDiagnostics (Basel, Switzerland)2026-10-16

Beyond Tuberculosis: Late Diagnosis of Cystic Fibrosis in an Adolescent with Bronchiectasis and Recurrent Pseudomonas aeruginosa Isolation: A Case Report.

Mihailov Oana Mariana OM, Luțenco Valerii V, Țocu Lavinia L, Mihailov Raul R et al.

Background and Clinical Significance: Cystic fibrosis may remain undiagnosed until adolescence, when recurrent respiratory infections and bronchiectasis are attributed to a previous severe infection. Case Presentation: We report the case of a male adolescent in whom approximately five years elapsed between microbiologically confirmed pulmonary tuberculosis in July 2021 and recognition of cystic fibrosis in August 2026. Archived records documented two sputum specimens that were acid-fast bacilli smear-positive (1+) and culture-positive (1+) for Mycobacterium tuberculosis complex. During adolescence, persistent bronchiectasis, recurrent Gram-negative respiratory infections, digital clubbing, and repeated Pseudomonas aeruginosa isolation prompted etiologic reassessment. A single documented sweat chloride concentration was 114 mmol/L. CFTR analysis of blood collected on 18 August 2026, reported on 16 September 2026, identified homozygous c.1521_1523delCTT (p.Phe508del; F508del), providing molecular confirmation. Spirometry showed FEV1 2.69 L (79.6% predicted), FVC 3.73 L (91.56% predicted), and FEV1/FVC 72.01% (z-score -2.58), consistent with airflow obstruction; without total lung capacity measurements, restriction or a mixed ventilatory defect could not be confirmed. The previously recorded azithromycin regimen was 500 mg orally three times weekly. Tobramycin inhalation solution 300 mg/5 mL was prescribed as one ampoule twice daily for 28 days, followed by 28 days off, with three planned cycles and salbutamol 15 min before administration. Management of cystic fibrosis also included airway-clearance therapy, dornase alfa 2.5 mg once daily, a high-calorie diet, pancreatic enzyme replacement, and vitamin supplementation. Longitudinal post-treatment spirometry, anthropometry, and validated quality-of-life measurements were not available. Conclusions: Previous pulmonary tuberculosis should not terminate etiologic investigation when bronchiectasis, repeated Pseudomonas aeruginosa isolation, digital clubbing, or progressive structural lung disease persists. Earlier recognition may permit earlier coordinated cystic fibrosis care and genotype-appropriate CFTR-modulator assessment.

PubMedAnalytical methods : advancing methods and applications2026-10-15

Fluorescent aptamer sensing of clenbuterol and salbutamol in artificial urine and construction of a proof-of-concept screening model.

Dong Qinfeng Q

A proof-of-concept differential dual-modal aptamer array was developed for clenbuterol (CLB) and salbutamol (SAL) screening in artificial urine. A CLB-selective aptamer and AP-Ago, a broad β2-agonist aptamer, were coupled to graphene-oxide fluorescence resonance energy transfer and to methylene-blue/ferrocene-labelled gold electrodes. Their four responses formed an analyte fingerprint by combining CLB-selective recognition with the broader response of AP-Ago. Seventy-two blind-coded samples represented six matrices, four screening classes and three independent preparation batches. Batches 1-2 (n = 48) supported model development, whereas batch 3 (n = 24; six samples per class) was locked for external assessment. Weighted calibration gave provisional procedural limits of detection of 0.083 ng mL-1 for CLB and 0.164 ng mL-1 for SAL. Mean external prediction-to-reference ratios were approximately 96% for CLB and 81% for SAL, distinct from controlled spike recoveries; intraday precision was 3.7% and interbatch precision was 5.8%. Against isotope-dilution LC-MS/MS, concordance correlation coefficients were 0.939 for CLB and 0.793 for SAL. A regularized multinomial logistic model achieved external balanced accuracy of 0.833, macro-F1 of 0.836 and Matthews correlation coefficient of 0.791. The reported bootstrap 95% confidence interval for balanced accuracy was 0.656-0.969, reflecting the small external set. The results support a candidate front-end triage strategy within the tested artificial matrices: differential signals identify presumptive CLB, SAL-associated high-response and mixed patterns, while any presumptive positive is referred for confirmatory LC-MS/MS rather than used for an anti-doping adjudication.

PubMedFrontiers in veterinary science2026-10-08

Comparative residue depletion and tissue distribution of three β-adrenergic agonists in broiler chickens.

Veseli Defrim D, Jovanov Stefan S, Hajrulai-Musliu Zehra Z

β-Adrenergic agonists are banned as growth promoters in the European Union, and clenbuterol and salbutamol are routinely screened in poultry under national residue-control programs; characterizing their residue behavior in edible tissues therefore supports the detection of illicit use. This study examined the residue depletion and tissue distribution of salbutamol, clenbuterol, and terbutaline in 168 Ross 308 broiler chickens. Each compound was administered in drinking water at 2.5 or 5 mg/L for seven consecutive days, chosen to model a covert exposure route rather than an authorized feed protocol, followed by a withdrawal period. Concentrations in breast muscle, liver, and kidney were quantified using a validated LC-MS/MS method compliant with Commission Implementing Regulation (EU) 2021/808. Residue values are group mean concentrations of three birds per group per sampling point (n = 3); because the individual per-bird results were not retained, no measures of dispersion are reported for the residue data. Quantifiable residues were detected in all three tissues at the first post-treatment sampling point, with the highest concentrations in kidney and liver and the lowest in breast muscle. Residues declined over the withdrawal period; terbutaline depleted most rapidly and clenbuterol persisted longest, and apparent depletion half-lives derived by log-linear regression were 1.1-1.5 days in liver and 0.7-1.2 days in kidney. By Day 46, all residues were below their respective matrix-specific decision limits (CCα), and no growth-promoting effect was observed for any compound at either concentration. Under this short drinking-water exposure, the three β-agonists showed distinct, tissue-dependent residue-depletion profiles but no measurable growth-promoting response in broilers. The comparative dataset, referenced to validated CCα values, supports residue surveillance and food-safety risk assessment of β-agonist residues in poultry.

PubMedPloS one2026-10-02

Efficacy of nebulized salbutamol in transient tachypnea of the newborn: A systematic review and meta-analysis.

Phattraprayoon Nanthida N, Koonrungsesomboon Nut N, Na Takuathung Mingkwan M

Transient tachypnea of the newborn (TTN) commonly affects near- and full-term infants and often requires respiratory support. The use of nebulized salbutamol to improve respiratory outcomes has been of interest, though its clinical efficacy remains controversial. This systematic review and meta-analysis aimed to evaluate whether nebulized salbutamol improves clinical outcomes in affected infants. We searched PubMed, Scopus, Embase, and the Cochrane Library for randomized controlled trials (RCTs) evaluating the efficacy of nebulized salbutamol in infants with TTN. We used a random-effects model to calculate mean differences (MDs) with 95% confidence intervals (CIs). Twenty-five studies were included in the systematic review, comprising seventeen RCTs for meta-analysis involving 1,317 infants. The analysis showed that salbutamol significantly decreased the duration of respiratory support (MD: -14.85 hours; 95% CI [-25.05, -4.65]; p = 0.004), duration of continuous positive airway pressure (MD: -18.19 hours; 95% CI [-30.03, -6.35]; p = 0.003), duration of oxygen requirement (MD: -24.57 hours; 95% CI [-35.03, -14.10]; p < 0.001), and length of hospitalization (MD: -1.17 days; 95% CI [-1.69, -0.65]; p < 0.001). However, there was no significant decrease in duration of tachypnea (MD: -9.93 hours; 95% CI [-25.42, 5.56]; p = 0.21) or duration of neonatal intensive care unit stay (MD: -0.84 days; 95% CI [-2.62, 0.94]; p = 0.36). Subgroup analysis for respiratory support duration showed no significant effect in infants with clinical score of TTN < 5 (MD: -10.88 hours; 95% CI [-24.48, 2.73]; p = 0.12), while the certainty of evidence for all outcomes was low to very low. Nebulized salbutamol may improve clinical outcomes relevant to the evolution of the disease in TTN infants, with potential benefits in certain subgroups such as those with greater disease severity, though the available evidence is of low to very low certainty. Therefore, our confidence in its efficacy in treating TTN remains limited.

PubMedIranian journal of allergy, asthma, and immunology2026-10-02

Clinical and Inflammatory Benefits of Nebulized Furosemide with Salbutamol-Ipratropium in COPD Exacerbations: A Randomized Controlled Trial.

Behi Mahdi M, Gholamine Babak B, Masjedi Mohammad Reza MR, Eslaminejad Alireza A et al.

Exacerbations of chronic obstructive pulmonary disease (COPD) are a leading cause of morbidity, mortality, and healthcare burden. While standard bronchodilator therapy alleviates airway obstruction, its efficacy is often limited. This study evaluated nebulized furosemide, which has bronchodilatory and anti-inflammatory effects, as an adjunct to salbutamol-ipratropium in hospitalized COPD patients. Ninety‑two patients with exacerbated COPD were randomly assigned to two equal groups (46 each). The intervention group received nebulized salbutamol-ipratropium plus furosemide (20 mg), and the control group received salbutamol-ipratropium, both every 8 hours for 10 minutes over 5 consecutive days. Demographic and clinical variables, pulmonary function indices (FEV1, FVC, FEV1/FVC), clinical outcomes (COPD Assessment Test (CAT), Modified Medical Research Council (mMRC)scores, and quality of life by St. George's Respiratory Questionnaire (SGRQ)), arterial blood gases, and inflammatory biomarkers (TNF-α, IL-6, IL-8, CRP, ESR, neutrophil %, WBC) were measured before and after treatment. Demographic characteristics and baseline indices did not differ significantly between the groups. Dyspnea and respiratory symptoms (mMRC and CAT scores) decreased significantly, while quality of life, improved markedly in the intervention group compared to the control group. Pulmonary function also showed significant enhancement, with the FEV₁/FVC ratio increasing. Arterial blood gas analysis showed higher PaO₂ and lower PaCO₂ in the intervention group. IL-6 and IL-8 decreased significantly, and no adverse events were reported. Nebulized furosemide enhances standard therapy in COPD exacerbations, improving lung function, relieving symptoms, and reducing systemic inflammation. Its safety, accessibility, and low cost make it a promising adjunct treatment.

PubMedERJ open research2026-09-29

Airway inflammation and asthma control in patients using salbutamol or budesonide/formoterol reliever: a randomised, controlled study.

Martin Matthew J MJ, Pavord Ian D ID, Chalmers James D JD, Saralaya Dinesh D et al.

Maintenance and reliever therapy (MART) with budesonide/formoterol (BUD/FORM) may offer asthma control with a single inhaler. This 6-month exploratory study monitored asthma symptoms, reliever use, lung function, airway inflammation and exacerbation events to determine treatment effectiveness in patients receiving BUD/FORM MART or BUD/FORM maintenance therapy plus short-acting β2-agonist (SABA). In the open-label STIFLE study (NCT03924635), patients were randomised to BUD/FORM MART (100 μg/6 μg or 200 μg/6 μg per inhalation, pro re nata (PRN)) or the same dose of BUD/FORM BID as maintenance therapy plus SABA (salbutamol) reliever PRN (100 μg per inhalation). Data were captured at home each day using devices connected to a smartphone via the STIFLE application. Occurrence of pre-defined exacerbation events required patients to attend hospital for assessment. 42 patients were randomised. Adherence to daily measurements exceeded 80% in both treatment groups. The proportion of patients experiencing an exacerbation was 27.8% in the BUD/FORM MART versus 70.8% in the BUD/FORM maintenance plus SABA group. A similar trend was observed in patients who experienced ≥1 day with ≥6 reliever uses (3 (16.7%) versus 9 (37.5%) patients, respectively). Patients treated with BUD/FORM MART showed less variation in airway inflammation, asthma symptom scores, lung function parameters and reliever use, versus BUD/FORM maintenance therapy plus SABA. No unexpected safety findings were observed. Patients with moderate asthma treated with BUD/FORM MART recorded less variation in asthma outcomes and lower rates of exacerbation events than those treated with BUD/FORM maintenance therapy plus SABA, suggesting improved asthma control.

+9026 more articles available with a free account

Sign up free to view all articles →

Ask about salbutamol